Acute Renal Failure (ARF) (Acute Kidney Injury) Competitive Insights, 2020: Emerging Therapies and Key pharma players involved by DelveInsight
DelveInsight launched a new report on Acute Renal Failure (Acute Kidney Injury) Pipeline Insights, 2020.
“Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Renal Failure (ARF) (Acute Kidney Injury) market. A detailed picture of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape is provided, which includes the disease overview and Acute Renal Failure (ARF) (Acute Kidney Injury) treatment guidelines.
Acute Kidney Injury (AKI) is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time.
Robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of Acute Kidney Injury market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of market which presently comprises of Biologics and molecules with new mechanisms of action.
Of the emerging therapies for AKI, the key players include ANG-3777 (BB3; Angion Biomedica), QPI1002 (Quark Pharmaceutical), ASP1128 (Astellas Pharma), MB-102 (MediBeacon), Ruconest (Conestat alfa; PharmingTechnologies), recAP (AM Pharma), bRESCAP (Alloksys), EA-230 (Exponential Biotherapies) and Simdax (Levosimendan; Orion Pharma).
Click here and get access to a free sample copy of the report.
Table of contents:
1. Report Introduction
2. Acute Renal Failure (ARF) (Acute Kidney Injury)
3. Acute Renal Failure (ARF) (Acute Kidney Injury) Current Treatment Patterns
4. Acute Renal Failure (ARF) (Acute Kidney Injury) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acute Renal Failure (ARF) (Acute Kidney Injury) Late Stage Products (Phase-III)
7. Acute Renal Failure (ARF) (Acute Kidney Injury) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Renal Failure (ARF) (Acute Kidney Injury) Discontinued Products
13. Acute Renal Failure (ARF) (Acute Kidney Injury) Product Profiles
14. Acute Renal Failure (ARF) (Acute Kidney Injury) Key Companies
15. Acute Renal Failure (ARF) (Acute Kidney Injury) Key Products
16. Dormant and Discontinued Products
17. Acute Renal Failure (ARF) (Acute Kidney Injury) Unmet Needs
18. Acute Renal Failure (ARF) (Acute Kidney Injury) Future Perspectives
19. Acute Renal Failure (ARF) (Acute Kidney Injury) Analyst Review
20. Appendix
21. Report Methodology
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
 (Acute Kidney Injury) Competitive Insights, 2020: Emerging Therapies and Key pharma players involved by DelveInsight){kind=link}